Literature DB >> 2390123

Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis.

P Miossec1, M Naviliat, A Dupuy d'Angeac, J Sany, J Banchereau.   

Abstract

Since interleukin-4 (IL-4) displays agonistic effects on both T and B cells, we studied whether this lymphokine is involved in rheumatoid synovitis, a disease characterized by intense T cell infiltration and B cell stimulation. Rheumatoid arthritis synovial fluids (RA SF) contained no (less than 15 pg/ml) or very low amounts (less than 25 pg/ml) of IL-4, as measured by a sensitive and specific enzyme-linked immunosorbent assay. No IL-4 was produced by unstimulated rheumatoid synovial membrane. RA SF were found to inhibit phorbol myristate acetate (PMA)-dependent proliferation of normal peripheral blood lymphocytes (PBL). An inhibitory fraction with an apparent molecular weight of 150 kd was isolated by gel filtration. The inhibitory fraction strongly blocked the proliferation of PBL induced by PMA, PMA + IL-2, or PMA + IL-4. However, this fraction was less effective in blocking the proliferation of PBL induced by PMA + IL-2 + IL-4. High levels of transforming growth factor beta (TGF beta) were found in these RA SF, and an anti-TGF beta antibody was able to partially reduce the inhibitory activity. RA SF were found to inhibit phytohemagglutinin-induced IL-4 production by PBL. These data indicate that IL-4, similar to other T cell lymphokines, cannot be detected in RA SF and that RA SF contains an inhibitory activity, related in part to TGF beta, which blocks mitogen-induced proliferation of PBL, at least in part through an inhibition of T cell-derived lymphokine release.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2390123     DOI: 10.1002/art.1780330819

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  54 in total

Review 1.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

2.  Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclo-oxygenase I.

Authors:  E Sugiyama; H Taki; A Kuroda; T Mino; N Yamashita; M Kobayashi
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

Review 3.  Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis.

Authors:  T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

4.  Simultaneous analysis of T cell clonality and cytokine production in rheumatoid arthritis using three-colour flow cytometry.

Authors:  P Bakakos; C Pickard; W M Wong; K R Ayre; J Madden; A J Frew; E Hodges; M I D Cawley; J L Smith
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

5.  Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells.

Authors:  E Robinson; E C Keystone; T J Schall; N Gillett; E N Fish
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

6.  Protection from interleukin 1 induced destruction of articular cartilage by transforming growth factor beta: studies in anatomically intact cartilage in vitro and in vivo.

Authors:  H M van Beuningen; P M van der Kraan; O J Arntz; W B van den Berg
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

7.  Reduction of tumor necrosis factor alpha and interleukin-1 beta levels in human synovial tissue by interleukin-4 and glucocorticoid.

Authors:  A Bendrups; A Hilton; A Meager; J A Hamilton
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

8.  Interaction of transforming growth factor-beta-1 with alpha-2-macroglobulin from normal and inflamed equine joints.

Authors:  N Coté; D R Trout; M A Hayes
Journal:  Can J Vet Res       Date:  1998-10       Impact factor: 1.310

9.  Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts.

Authors:  R C Borghaei; P L Rawlings; E Mochan
Journal:  Arthritis Rheum       Date:  1998-08

10.  Antibodies to major histocompatibility complex class II inhibit proliferation, but increase production of soluble CD23 in lymphoblastoid B-cell lines.

Authors:  A H Hajeer; N Snowden; P Wilson; S Drover; W E Ollier
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.